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T he therapy for locally advanced non-small-cell lung cancer (NSCLC) remains controversial [1-7].  
Definitive chemoradiotherapy (CRT) is considered a 
standard therapy in the curative management of the 
disease,  and concurrent administration of taxanes with 
radiotherapy (RT) has shown good results [8 , 9].  
However,  inadequate local control outcomes have led to 
various treatment strategies that incorporate surgical 
resection [1].  Meta-analyses of individual participant 
data regarding preoperative chemotherapy have shown 
improved survival for patients with mainly stage IB-IIIA 
NSCLC [10].  In addition,  some attempts at incorpo-
rating radiotherapy into the induction program have 
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To clarify the relationship between dose-volume histogram (DVH) parameters and radiation pneumonitis (RP) 
after surgery in cases of non-small cell lung cancer (NSCLC) treated with induction concurrent chemoradio-
therapy (CCRT).  Patients with NSCLC treated with induction CCRT (chemotherapy: cisplatin and 
docetaxel; radiotherapy: 2.0 Gy fractions once daily for a total of 46 Gy) before surgery were reviewed.  We 
calculated the percentage of lung volume receiving at least 20 Gy (V20) and the mean lung dose (MLD) for the 
total lung volume and the lung remaining after resection.  Factors affecting the incidence of RP at grade 2 or 
higher (≥ G2 RP) were analyzed.  Eighteen of 49 patients (37%) experienced ≥ G2 RP.  The V20 and MLD for the 
lung remaining after resection (V20r and MLDr) were significant predictors according to the multivariate anal-
ysis (p= 0.007 and 0.041,  respectively).  The incidence of ≥ G2 RP was 8% in patients with V20r < 10%,  and 13% 
in patients with MLDr < 5.6 Gy,  respectively.  The optimal approach to reduce the rate of postoperative RP in 
patients with induction CCRT for NSCLC is to keep the V20r below 10% and/or the MLDr below 5.6 Gy in the 
radiotherapy planning.
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been made.  In INT0139,  a phase III randomized con-
trolled trial compared the concurrent CRT (CCRT) 
followed by surgery with definitive CCRT in patients 
with stage III NSCLC,  and found that OS was not 
significantly improved in patients who underwent tri-
modal treatment.  In an exploratory analysis,  in com-
parison to patients who received definitive CCRT,  OS 
was improved for patients who underwent lobectomy,  
but not pneumonectomy [7].  Toyooka et al.  showed that 
the 3-year and 5-year OS of patients who underwent 
induction CCRT were significantly higher than those of 
patients who underwent induction chemotherapy [6].  
In the National Comprehensive Cancer Network Clinical 
Practice Guidelines in Oncology: version 3.2018 
<https://www.nccn.org/professionals/physician_gls/
pdf/nscl_blocks.pdf>(accessed April,  208),  induction 
CCRT is recommended for resectable superior sulcus 
tumors and is an option for patients with resectable 
stage IIIA tumors (minimal N2 and treatable with 
lobectomy).  
Symptomatic radiation pneumonitis (RP) is a clini-
cally important toxicity in patients undergoing CRT for 
NSCLC [11].  Several previous studies have reported 
correlations between radiation dose-volume histogram 
(DVH) parameters and pneumonitis [11-13].  The per-
centage of lung volume receiving at least 20 Gy (V20) 
and mean lung dose (MLD) are frequently associated 
with pneumonitis and are the most commonly used 
DVH parameters in clinical practice.  Recently,  
Takahashi et al.  published the first report to examine the 
relationship between RP and DVH parameters in 
patients with NSCLC undergoing induction CRT [14].  
The V20 values of the lung remaining after resection 
(V20r) and lobectomy were significant factors according 
to a univariate analysis,  but no factor was found to be 
significant based on multivariate analysis.  In addition,  
there were some problems in their report.  For example,  
the regimen of chemotherapy was not unified.  
Chemotherapy is a risk factor for RP [11],  and there-
fore the variation in the chemotherapy regimen may 
have influenced the results of their analysis.  In addi-
tion,  their study included some patients who experi-
enced RP before surgery.  Because V20r is determined 
by the results of surgery,  V20r cannot be a predictor of 
preoperative RP.
In the present study,  we investigated the predictors 
of RP after surgery with induction CCRT for NSCLC 
patients.  We selected the patients who received the 
same chemotherapy regimen and who had an onset of 
RP only after surgery.
Materials and Methods
Patients. Data on 84 NSCLC patients who 
received induction CCRT at Okayama University 
Hospital between January 2003 and December 2011 
were reviewed.  NSCLC was confirmed histologically 
before treatment.  Induction CCRT was given for 
patients with potentially resectable N2/3 or bulky N1 
tumors.  Eligible patients were required to be treated 
with RT with a total dose of 46 Gy in 23 fractions,  che-
motherapy using cisplatin/docetaxel administered con-
currently with RT,  and the surgery conducted following 
induction CCRT.  Patients who had an onset of pneu-
monia or pneumonitis before surgery were excluded.  
This retrospective study complied with the Declaration 
of Helsinki 1989 recommendations.  Patients who 
received induction CCRT provided consent to partici-
pate in the study through an opt-out methodology,  by 
displaying a notice in the outpatient ward and on the 
website.  The institutional review board of Okayama 
University approved this study (approval number 2214).
Treatment. The staging workup included a phys-
ical examination,  chest X-ray,  CT scan of the chest and 
abdomen,  MRI scan of the brain,  and a bone scan or 
positron emission tomography integrated with a fluoro-
deoxyglucose-computed tomography scan.  The RT 
treatment planning was based on 2-10 mm thick,  and 
2-10 mm-interval CT scans obtained in the supine 
position with both arms up,  breathing freely.  RT tar-
gets were defined according to the International 
Commission on Radiation Units and Measurements 
Report Numbers 50 and 62.  The gross tumor volume 
(GTV) included the primary tumors and clinically 
diagnosed metastatic lymph nodes.  The clinical target 
volume (CTV) included the GTV with a 5-10 mm mar-
gin and uninvolved subcarinal and ipsilateral hilar 
lymph nodes.  The planning target volume (PTV) 
included the clinical target volume with a 5-10 mm 
margin,  with consideration for the internal and setup 
margin.  All patients underwent 3D treatment planning 
using computer software (Xio version 4.8.0,  Elekta,  
Sweden) with a superposition dose calculation algo-
rithm for heterogeneity correction.  RT was delivered 
using a linear accelerator (Mevatron KD2,  Canon,  
Japan) with a 10-MV photon beam and with conven-
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tional fractionation.  Generally,  the prescribed dose to 
the isocenter or reference point in the PTV was 46 Gy at 
2-Gy fractions once daily,  5 days/week.  The beam 
arrangements were typically 2 opposed anterior-poste-
rior fields followed by off-cord oblique fields.  
Chemotherapy was given concurrently with RT as the 
initial treatment.  The chemotherapy regimen was cis-
platin/docetaxel.  Surgery was conducted about one 
month after completion of RT.  Consolidation chemo-
therapy was not executed.
Evaluation. The lungs were considered together 
as a single-paired organ.  Lung contours were obtained 
automatically by the CT threshold,  the trachea and 
bronchi were excluded manually,  and the GTV within 
the lung was also excluded.  As DVH parameters,  V20 
and MLD were calculated from the total lung volume 
and the lung volume remaining after resection (V20r 
and MLDr).  The terms “V20r” and “MLDr” were 
adapted from Takahahi’s article [14].  Portions of the 
lung resected at the initial surgery were determined 
according to the surgical records.
After treatment completion,  patients were fol-
lowed-up every 1-2 months on an outpatient basis while 
the patient’s general status was stable.  The RP was 
graded according to the Common Terminology Criteria 
for Adverse Events,  version 4.0.  The association 
between grade 2 or higher RP (≥ G2 RP) and DVH 
parameters was analyzed.  Univariate analyses by 
Fisher’s exact test and a multivariate analysis by the Cox 
proportional hazards model were performed using R 
software,  version 3.2.0 (R Foundation for Statistical 
Computing) to assess patient- and treatment-related 
factors in addition to DVH parameters.  We used the 
median cut-off value in order to convert continuous 
parameters into binomial parameters before executing 
Fisher’s exact test.  A p value of less than 0.05 was con-
sidered significant.  The cumulative incidence rate of RP 
was presented as a Kaplan-Meier curve with stratifica-
tion of significant factors in the multivariate analysis.
Results
Forty-nine patients were examined in this study.  
The patient characteristics are shown in Table 1.  The 
clinical stage according to the 7th edition of the Union 
for International Cancer Control TNM classification 
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Table 1　 Patient characteristics
%
Age (year) Median (range) 60 (46-79) -
Gender Male 34 69
Female 15 31
ECOG-PS 0 30 61
1 19 39
Smoking history (pack-year)a Median (range) 41 (0-135) -
Lobe Upper 30 61
Middle  4 8
Lower 15 31
Histology Adenocarcinoma 24 49
Squamous cell carcinoma 17 35
Non-small cell carcinoma  8 16
c-stage IIA  2 4
IIB  3 6
IIIA 26 53
IIIB 18 37
FEV1 (L)a Median (range)  2.5 (1.4-3.9) -
Period from completion of 
RT to surgery (weeks)
Median (range)  5 (3-9) -
Surgery Pneumonectomy  5 10
Bilobectomy  7 14
Lobectomy 37 76
ECOG-PS,  Eastern Cooperative Oncology Group-Performance Status; FEV1,  forced expiratory volume in 1 sec; RT,  radiotherapy.
aThese factors have missing values.
was IIA in 2 patients,  IIB in 3 patients,  IIIA in 26 
patients and IIIB in 18 patients.  All of the 49 patients 
were pathologically diagnosed before surgery; 24 had 
adenocarcinoma,  17 had squamous cell carcinoma and 
the remaining 8 had non-small cell lung carcinoma.  
The median baseline forced expiratory volume in 1 sec-
ond was 2.5 l (range: 1.4-3.9).  All the patients received 
induction CCRT with a dose of 46 Gy.  The median 
interval to surgery was 5 weeks (range: 3-9 weeks).  A 
lobectomy was performed in 37 patients,  a bilobectomy 
in 7 patients and a pneumonectomy in 5 patients.
The median follow-up period was 28.9 months 
(range: 2.7-108.3).  RP developed in the study patients 
as follows: grade 0 in 16 patients,  grade 1 in 15,  grade 
2 in 17,  and grade 3 in 1 patient.  Eighteen (37%) 
patients experienced ≥ G2 RP.  The median period from 
completion of RT to the onset of ≥ G2 RP was 8.1 weeks 
(range: 4.6-18.6 weeks).  The cumulative incidence rate 
of ≥ G2 RP is presented as a Kaplan-Meier curve (Fig.1).  
The rate at 6 months was 37% (32-49%,  95% confiden-
tial interval).  The results of univariate or multivariate 
analyses of factors associated with ≥ G2 RP are shown in 
Table 2.  A V20 ≥ 23% and V20r ≥ 10% were found to be 
statistically significant factors in the univariate analyses 
(p = 0.016 and 0.0002,  respectively).  An MLD ≥ 10.8 Gy 
and MLDr ≥ 5.6 Gy were also found to be significant 
factors in the univariate analysis (p = 0.002 and 0.009,  
respectively).  Patient age,  smoking history,  gender,  
and tumor location,  which were associated with a risk 
of developing RP after CRT in the previous report [15],  
did not make a significant contribution to the develop-
ment of ≥ G2 RP in our study.  V20r and MLDr were 
also significant factors in the multivariate analysis 
(p = 0.007 and 0.041,  respectively).  With stratification 
for V20r and MLDr,  the cumulative incidence rate of 
≥ G2 RP is presented as a Kaplan-Meier curve (Fig.  
2A , 2B).  The rates at 6 months were 8% and 62% in 
patients with V20r < 10% and ≥ 10%,  respectively,  and 
13% and 60% in patients with MLDr < 5.6 Gy and ≥ 5.6 
Gy,  respectively.
Discussion
In the treatment of NSCLC,  RP often occurs after 
surgery with induction CRT [7 , 14 , 16].  The DVH 
parameters,  such as V20 and MLD,  are useful predic-
tors of RP in the definitive RT with or without chemo-
therapy [11-13 , 15 , 17-21].  Graham et al.  reported that 
V20 was the only single independent predictor of RP in 
their patients undergoing definitive RT [17].  In their 
report,  when the V20 was less than 22%,  there was no 
pneumonitis,  and when the V20 was 22-31% there was 
an 8% chance of developing grade 2 pneumonitis,  but 
no higher severity.  Tsujino et al.  showed that V20 was 
the only factor associated with ≥ G2 RP after CCRT 
[13].  The 6-month cumulative incidence of ≥ G2 RP 
was 14% in their patients with V20 ≤ 25% and 63% in 
those with V20 ≥ 26%.  Palma et al.  reported that the 
rate of RP was 18.6% in patients with V20 < 20% in their 
meta-analysis [11].  According to these researchers,  the 
incidence of fatal pneumonitis was 2.9% and 3.5% in 
patients with V20 30-40% and ≥ 40%,  respectively.  
Some authors have reported observing a relationship 
between MLD and RP after definitive radiotherapy with 
or without chemotherapy [11 , 13 , 15 , 18 , 21].  Barriger 
et al.  reported that 2.2% of patients with MLD < 18 Gy 
had ≥ G2 RP compared to 19% of patients with 
MLD > 18 Gy [13].  As the result of a recursive parti-
tioning analysis,  Palma et al.  showed that the rates of 
RP in patients aged ≤ 65 years and treated with carbo-
platin/paclitaxel chemotherapy were 0-9% and 41-48% 
in those with MLD < 10 Gy and ≥ 10 Gy,  respectively 
[11].  In our study,  the cumulative rates of ≥ G2 RP at 
6 months were 8% and 62% in patients with V20r < 10% 
and ≥ 10%,  respectively.  In patients with MLDr < 5.6 Gy 
and ≥ 5.6 Gy,  the rates were 13% and 60%,  respectively.  
These cut-off values were lower than those of previous 
studies on definitive CRT.
Recently,  Takahashi et al.  issued the first report to 
examine the relationship between radiation pneumoni-
tis and DVH parameters in patients with NSCLC with 
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Fig. 1　 Cumulative incidence rate of radiation pneumonitis at 
grade 2 or higher after completion of radiotherapy.  The broken lines 
indicate 95% conﬁdential intervals.
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Fig. 2　 A,  Cumulative incidence rate of radiation pneumonitis at grade 2 or higher after completion of radiotherapy,  stratiﬁed according 
to the percentage of the lung volume remaining after resection receiving at least 20 Gy (V20r); B,  Cumulative incidence rate of radiation 
pneumonitis at grade 2 or higher after completion of radiotherapy,  stratiﬁed according to the mean lung dose of the lung remaining after 
resection (MLDr).
Table 2　 Univariate and multivariate analyses of factors associated with radiation pneumonitis at grade 2 or higher
Factor n Univariate p-value 
Odds ratio  
(95% CI)
Multivariate 
p-value
Age (year) <60  9/26 0.775 - NE
≥60  9/23
Gender Male 13/34 1.000 - NE
Female  5/15
ECOG-PS 0 10/30 0.559 - NE
1  8/19
Smoking history <41 10/23 0.542 - NE
(pack-year)a ≥41  7/23
Lower lobe  9/15 0.051 - NE
Upper/Middle lobe  9/34
Lobectomy 11/37 0.094 - NE
Bilobectomy/Pneu-
　monectomy
 7/12
FEV 1 (L)a <2.5  7/21 0.759 - NE
≥2.5 10/24
Total lung <3,171 10/24 0.561 - NE
Volume (ml) ≥3,171  8/25
V20 (%) <23  5/25 0.016 5.34 0.351
≥23 13/24 (1.27-27.74)
MLD (Gy) <10.8  3/23 0.002 8.65 0.107
≥10.8 15/26 (1.88-56.90)
Total lung volume <2,429 10/24 0.561 - NE
Remaining after ≥2,429  8/25
　resection (ml)
V20r (%) <10  2/23 0.0002 15.73 0.007
≥10 16/26 (2.86-167.11)
MLDr (Gy) <5.6  3/24 0.0009 9.94 0.041
≥5.6 15/25 (2.14-66.08)
CI,  conﬁdence interval; NE,  not entered; ECOG-PS,  Eastern Cooperative Oncology Group Performance Status; FEV 1,  forced expiratory 
volume in 1 sec; MLD,  mean lung dose of the total lung; MLDr,  mean lung dose of the lung remaining after resection; V20,  percentage 
of the total lung volume receiving at least 20 Gy; V20r,  percentage of the lung volume remaining after resection receiving at least 20 Gy.
aThese factors have missing values.
induction CCRT [14].  In their report,  the rates of ≥ G2 
RP were 22% and 55% in patients with V20r ≤ 11% 
and ≥ 12%,  respectively.  A V20r ≥ 12% and lobectomy 
were significant factors in the univariate analysis,  but 
these factors were not found to be significant in the 
multivariate analysis.  The MLD was not a significant 
factor even in the univariate analysis.  We have shown 
that the risk of ≥ G2 RP is significantly higher when 
V20r ≥ 10% and/or MLDr ≥ 5.6 Gy in univariate and 
multivariate analyses.
Palma et al.  found that the predictors of radiation 
pneumonitis were V20 (odds ratio [OR] 1.03) and che-
motherapy regimen (OR for carboplatin/paclitaxel 3.33,  
relative to cisplatin/etoposide) on multivariate analysis 
[11].  Barriger et al.  reported that consolidation chemo-
therapy with docetaxel after CCRT was a predictive 
factor for RP [13].  These reports suggest that the use of 
taxane agents is a risk factor for RP.  Whereas the che-
motherapy regimen was cisplatin/docetaxel in all 
patients in our study,  the regimens of Takahashi’s study 
were various,  including regimens without taxane.  The 
difference in chemotherapy regimens may account for 
the different results between their study and ours.  In 
addition,  ≥ G2 RP occurred preoperatively in 9 out of 
16 patients with ≥ G2 RP in Takahashi’s report [14].  RP 
typically occurs within radiation fields,  and thus RP 
that occurred preoperatively would be expected to 
locate mostly within the lung around the tumor,  which 
would be resected thereafter.  We think that in the case 
of preoperative RP patients,  it is appropriate to investi-
gate the risk of RP in relation to the V20 or MLD from 
the total lung volume,  including the volume of the later 
resected parts,  as in other studies concerning definitive 
RT.  Because the risk factors of RP may be different 
between preoperative and postoperative cases,  to lump 
both cases together might lead to unreliable results.
Takahashi et al.  reported that a lobectomy was 
another significant factor compared to a bilobectomy/
pneumonectomy in a univariate analysis [14],  but in 
our study,  it was not a significant factor.  In their report,  
the incidence of RP was 40% in those with a lobectomy 
and 14% in those with a bilobectomy/pneumonectomy,  
whereas in our report,  the incidence was 30% and 58%,  
respectively.  Because patients with preoperative RP 
were included in their study,  this may account for the 
difference.  In an exploratory analysis of INT0139,  OS 
was improved for patients who underwent lobectomy 
after induction CRT versus definitive CRT [7].  From 
the point of view of not only treatment prognosis but 
also adverse events,  induction CRT should be indicated 
in cases treatable with lobectomy.
Some authors have reported that the rate of ≥ G2 RP 
was 7-35% in patients with definitive CRT [12 , 13 , 21].  
In our study,  although the total radiation dose was no 
more than 46 Gy and much of the lung exposed to a 
relatively high radiation dose was resected,  the rate of 
RP was 36% and higher than those in previous reports.  
Sugiura et al.  reported that 4.8% of patients who were 
histologically diagnosed with usual interstitial pneumo-
nia experienced postoperative acute exacerbation [22].  
In the INT0139 trial,  6% of patients who underwent 
surgery after induction CRT died of acute respiratory 
distress syndrome and other types of respiratory failure 
[7].  In addition to chemotherapy including taxane 
agents,  surgical invasion may account for the relatively 
high rate of RP in our study.
Acute RP most commonly manifests in the first 
6 months after RT completion [15].  The median period 
before onset of RP after definite radiotherapy was 
reported to be 41 days [19] or 2.7 months [20].  In our 
study,  the period after induction CRT was 8.1 weeks,  
which is almost the same as in the above reports but 
longer than the 5.5 weeks reported in Takahashi’s study 
[14].  Excluding patients with preoperative RP in our 
study may account for this difference.
To the best of our knowledge,  ours is the first study 
to indicate that V20r and MLDr are significant predic-
tors of RP after surgery with induction CCRT for 
NSCLC.  However,  our study has certain limitations.  
This was a retrospective study and the diagnosis of RP 
was somewhat uncertain.  We determined the diagnos-
tic criteria of RP before reviewing patient records,  but 
grading of RP was sometimes confusing because it was 
based on past medical records.  Kocak et al.  reported 
that scoring of radiation pneumonitis was difficult in 
28% of patients treated for lung cancer owing to con-
founding medical conditions [23].  The uncertainty in 
grading RP might also have had some influence over the 
results of our analysis.
In conclusion,  we found that V20r and MLDr were 
the predictors of ≥ G2 RP after surgery with induction 
CCRT for our NSCLC patients.  Therefore,  to reduce 
the rate of RP after surgery,  it is important to consider 
V20r and MLDr in the planning of radiotherapy.  
Newer technologies,  such as intensity modulated radi-
ation therapy,  may make it easier to keep V20r and 
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MLDr as low as possible without sacrificing the tumor 
control and increasing adverse events other than RP 
after surgery
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